ReviewClinical interventions in aging2022
How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review.
Review in Clinical interventions in aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Global prevalence of chronic kidney disease and its influencing factors among chronic hepatitis B: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications.Portal hypertension & cirrhosis · 2026Review
- Global, regional, and national burden of liver cancer due to hepatitis B, 1990-2021 and projections to 2051: a systematic analysis of the Global Burden of Disease Study 2021.European journal of gastroenterology & hepatology · 2026Article
- Chronic comorbidities, concomitant medications, and treatment patterns of chronic hepatitis B patients receiving nucleos(t)ide analogue therapy: a hospital claims database study in Japan.BMC infectious diseases · 2026Observational
- Short- and Long-Term Healthcare Costs Attributable to Hepatitis B Among Newcomers to Ontario, Canada: A Matched Cohort Study.Canadian journal of gastroenterology & hepatology · 2026Article
- Epidemiological analysis of infectious diseases in older people in China from 2014 to 2022: a population-based study.The Lancet regional health. Western Pacific · 2025Article
- Global, regional, and national total burden related to hepatitis B and attributable risk factors in adults aged 65 years and older from 1990 to 2021 and projection to 2030.Frontiers in public health · 2025Article
- Inpatient Cost Burdens of Treating Chronic Hepatitis B in US Hospitals: A Weighted Analysis of a National Database.Digestive diseases and sciences · 2024Article
- Current perspectives of viral hepatitis.World journal of gastroenterology · 2024Review
- Determination of Seroprevalence of Chronic Hepatitis B, C and D: A Cross-Sectional Study From Türkiye.Public health nursing (Boston, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) infection is a major global public health challenge associated with significant morbidity and mortality. Due to worldwide population aging, HBV infection in the elderly will become increasingly prevalent. Effective universal vaccination programs exist but these are largely targeted towards the younger population. Therefore, the elderly population remains at risk of higher disease burden. New diagnoses of HBV infection in the elderly are usually asymptomatic chronic infections which increases their risk of developing cirrhosis, hepatocellular carcinoma, and liver disease-related mortality, especially if left untreated. Physiological changes and the increasing prevalence of multimorbidity associated with aging also potentially worsen outcomes in elderly patients with chronic HBV infection. Therefore, this cohort of patients should be monitored closely and effectively. Current international clinical practice guidelines unfortunately do not provide hard treatment endpoints specific to elderly patients with chronic HBV infection. Management of these patients is complex and requires an individualized approach. Multiple factors such as physiological changes, comorbidities, compliance, treatment tolerability and efficacy, burden of treatment, and realistic treatment goals need to be considered. Shared decision-making between patient and clinician is essential to ensure that the final decision for or against treatment aligns with the patient's values and preferences. This review article aims to summarize the monitoring and management of chronic HBV infection in the aging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.